NO20064788L - Anti-myostatin-anistoffer - Google Patents

Anti-myostatin-anistoffer

Info

Publication number
NO20064788L
NO20064788L NO20064788A NO20064788A NO20064788L NO 20064788 L NO20064788 L NO 20064788L NO 20064788 A NO20064788 A NO 20064788A NO 20064788 A NO20064788 A NO 20064788A NO 20064788 L NO20064788 L NO 20064788L
Authority
NO
Norway
Prior art keywords
antibodies
myostatin
epitope
anistoffer
increasing
Prior art date
Application number
NO20064788A
Other languages
English (en)
Inventor
Kristine Kay Kikly
Rosamund Carol Smith
Linda O Tobias
Bomie Han
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35064367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064788(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20064788L publication Critical patent/NO20064788L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)

Abstract

Sammendrag 0. nr. P60601579NO00 Det identifiseres en nøytraliserende epitop innen aminosyrene 40-64 av den mature form av human myostatin. Antistoffer som binder denne epitop faller innenfor rammen av oppfinnelsen og kan være murine, kimere eller humaniserte antistoffer, immunokonjugater av antistoffer eller antigenbindende fragmenter derav. Antistoffene ifølge oppfinnelsen er brukbare for å øke muskelmassen, å øke bendensiteten eller for behandling av forskjellige sykdommer i pattedyr.
NO20064788A 2004-03-23 2006-10-23 Anti-myostatin-anistoffer NO20064788L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55545604P 2004-03-23 2004-03-23
US55962104P 2004-04-05 2004-04-05
PCT/US2005/009307 WO2005094446A2 (en) 2004-03-23 2005-03-17 Anti-myostatin antibodies

Publications (1)

Publication Number Publication Date
NO20064788L true NO20064788L (no) 2006-12-05

Family

ID=35064367

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064788A NO20064788L (no) 2004-03-23 2006-10-23 Anti-myostatin-anistoffer

Country Status (14)

Country Link
US (1) US20070178095A1 (no)
EP (1) EP1733041B1 (no)
JP (1) JP4695133B2 (no)
KR (1) KR20060133049A (no)
AT (1) ATE557042T1 (no)
AU (1) AU2005227896B2 (no)
BR (1) BRPI0508716A (no)
CA (1) CA2558805C (no)
EA (1) EA014112B1 (no)
ES (1) ES2384176T3 (no)
IL (1) IL177956A (no)
MX (1) MXPA06010929A (no)
NO (1) NO20064788L (no)
WO (1) WO2005094446A2 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541253A (en) 2002-12-20 2010-03-26 Amgen Inc Peptide binding agents which inhibit myostatin
US7807159B2 (en) * 2005-04-25 2010-10-05 Amgen Fremont Inc. Antibodies to myostatin
WO2007044411A2 (en) * 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
MX2008007324A (es) * 2005-12-06 2009-03-04 Amgen Inc Usos de antagonistas de miostatina.
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5058261B2 (ja) * 2006-09-05 2012-10-24 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
EP2170396B1 (en) 2007-08-03 2016-12-21 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009041643A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Cdrのアミノ酸置換により抗体の等電点を改変する方法
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
JP4954326B2 (ja) 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
HUP0800448A2 (en) * 2008-07-21 2011-02-28 Pecsi Tudomanyegyetem Diagnosis of systemic diseases
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
FR2943249B1 (fr) * 2009-03-18 2011-08-12 Genethon Utilisation de la decorine pour augmenter la masse musculaire
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
EP4231014A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
PL2780368T3 (pl) 2011-11-14 2018-06-29 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A
FR2982860B1 (fr) 2011-11-18 2015-07-10 Ass Fr Contre Les Myopathies Utilisation de la fibromoduline et du lumican pour augmenter la masse musculaire
ES2698606T3 (es) * 2012-01-20 2019-02-05 Genzyme Corp Anticuerpos anti-CXCR3
WO2013186719A1 (en) * 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
RS60318B1 (sr) 2012-08-01 2020-07-31 Ikaika Therapeutics Llc Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitela
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
NZ705370A (en) 2012-08-24 2018-06-29 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
MY172863A (en) 2012-09-13 2019-12-13 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
WO2014168973A2 (en) 2013-04-08 2014-10-16 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3881859B1 (en) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015143126A1 (en) 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
CA2982810A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
US11359009B2 (en) * 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3949979A1 (en) 2016-01-06 2022-02-09 President and Fellows of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
MX2018008369A (es) 2016-01-08 2019-05-15 Scholar Rock Inc Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
AU2017285764B2 (en) 2016-06-17 2024-05-02 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
DK3565592T3 (da) * 2017-01-06 2023-05-01 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
CA3092334A1 (en) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
WO2020131910A1 (en) 2018-12-18 2020-06-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US20240199728A1 (en) 2022-09-21 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
EP1333035A3 (en) * 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
AU690474B2 (en) * 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
JP4544742B2 (ja) * 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
US6537781B1 (en) * 1999-08-10 2003-03-25 Idexx Laboratories, Inc. Methods and compositions concerning canine interleukin 5
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof

Also Published As

Publication number Publication date
EA200601752A1 (ru) 2007-02-27
JP2007530551A (ja) 2007-11-01
WO2005094446A3 (en) 2005-12-22
EP1733041B1 (en) 2012-05-09
CA2558805A1 (en) 2005-10-13
KR20060133049A (ko) 2006-12-22
JP4695133B2 (ja) 2011-06-08
IL177956A (en) 2010-11-30
EP1733041A2 (en) 2006-12-20
BRPI0508716A (pt) 2007-08-07
EA014112B1 (ru) 2010-10-29
AU2005227896A1 (en) 2005-10-13
ATE557042T1 (de) 2012-05-15
MXPA06010929A (es) 2007-01-16
IL177956A0 (en) 2006-12-31
US20070178095A1 (en) 2007-08-02
AU2005227896B2 (en) 2008-11-13
EP1733041A4 (en) 2009-01-28
WO2005094446A2 (en) 2005-10-13
CA2558805C (en) 2011-09-27
ES2384176T3 (es) 2012-07-02

Similar Documents

Publication Publication Date Title
EA200601752A1 (ru) Антимиостатиновые антитела
WO2007044411A3 (en) Anti-myostatin antibodies
UA92504C2 (en) Anti-myostatin monoclonal antibody
NL301196I2 (nl) inebilizumab
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
UA109633C2 (uk) Антитіло людини проти тканинного фактора
TN2009000383A1 (en) Anti - sclerostin antibodies
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы
DK3284753T3 (da) Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
IL187594A0 (en) Humanized anti-cd40 antibodies and their methods of use
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
CR20220047A (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
WO2003073982A3 (en) Anti-interleukin-1 beta analogs
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
WO2007101021A3 (en) Humanized anti-ghrelin antibodies
ZA202205813B (en) Trpv1 epitopes and antibodies
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
CY1115979T1 (el) Αντισωματα κατα της μυοστατινης
CY1116887T1 (el) Anti-cd19 αντισωματα και χρησεις στην ογκολογια

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application